ArticlePoultry science2026
A Self-amplifying mRNA vaccine for infectious laryngotracheitis virus (ILTV) induces efficient protective immunity.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alphavirus replicase and regulatory RNA elements in host interactions and viral vector engineering.Journal of virology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious laryngotracheitis (ILT) continues to pose a significant threat to intensive poultry farming regions worldwide. Current control strategies primarily rely on live attenuated and recombinant live ILT virus (ILTV) vaccines. However, concerns persist regarding the potential reversion to virulence, recombination of vaccine viruses, and interference from maternal antibodies. mRNA vaccine platforms offer a novel and promising approach for developing next-generation ILTV vaccines. In this study, we designed a self-amplifying RNA (saRNA) vaccine incorporating the ILTV gD gene and evaluated its immunogenicity and protective efficacy in chickens. The saRNA-gD vaccine elicited robust humoral immunity, with serum neutralizing antibody titers reaching up to 1:415. All vaccinated chickens achieved seropositivity within 7 days post-vaccination (dpv). Significantly elevated levels of IL-2 cytokine were observed at 28 and 42 dpv compared to the LNP control group, suggesting the potential activation of cellular immune responses following vaccination. Animal challenge experiment revealed that the saRNA-gD vaccine effectively mitigated clinical symptoms induced by ILTV infection, conferring a protection rate of approximately 66.7%, which is comparable to that of the commercial recombinant fowl pox virus (rFPV-LT) vaccine. Quantification of viral loads in tracheal swabs and histopathological examination demonstrated that the saRNA-gD vaccine significantly reduced viral DNA copies in swabs and induced markedly milder histopathological changes. These findings indicate that the saRNA-gD vaccine induces potent immune responses and provides substantial protection against ILTV challenge, potentiating it as a highly promising vaccine candidate for the control of ILT in poultry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.